News | April 25, 2013

Toshiba Partners With Leading Universities for Advanced MR Research

Introduces new sequence development environment at ISMRM

April 25, 2013 — Leading research institutions are making breakthroughs in advanced magnetic resonance (MR) imaging with Toshiba America Medical Systems Inc.’s Vantage Titan 3.0T MR system. Toshiba has partnered with Shands at the University of Florida and the Keck Medical Center of the University of Southern California (USC) for MR clinical research in functional MRI (fMRI), as well as body and cardiac imaging.

 “We’re utilizing the Titan 3.0T MR to enhance visualization of cerebral spinal fluid (CSF) flow non-invasively and in the research of traumatic brain injuries from combat and athletics,” said Anthony Mancuso, professor and chairman of the department of radiology, UF College of Medicine. “The Titan 3.0T fulfills all the promises of a high-end 3.0T system, with high image quality, gradient homogeneity and patient-focused features.”

As part of Toshiba’s commitment to supporting institutions in advanced MR research, Toshiba is demonstrating the new sequence development environment (NSDE), a research-only tool that allows the research community to develop its own pulse sequences to explore new applications of MR imaging.

“Partnering with prestigious universities such as USC and Shands at the University of Florida illustrates our commitment to developing advanced technology that can expand the potential clinical applications of MR imaging,” said Suresh Narayan, senior manager, market development, MR business unit, Toshiba.

Toshiba showcased the Titan 3.0T with NSDE at this year’s International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting in Salt Lake City, April 20-26, 2013.

For more information: www.medical.toshiba.com


Related Content

News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
Subscribe Now